Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

28.09.22	MÄRKTE USA/Börsen starten zurückhaltend - Biogen mit Kurssprung (Dow Jones)
28.09.22	MÄRKTE USA/Aktien mit Abschlägen erwarten - Biogen mit Kurssprung (Dow Jones)
28.09.22	Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… (RTTNews)
28.09.22	MARKT USA/Aktien vor weiteren Einbussen - Biogen haussieren (Dow Jones)
28.09.22	Biogen And Eisai's Lecanemab Slows Progression Of Alzheimer's Disease In Phase 3 Trial (RTTNews)
28.09.22	LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WI... (PR Newswire)
27.09.22	Biogen Agrees To Pay $900 Mln Over Kickback Allegations (RTTNews)
21.09.22	The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS (GlobeNewswire)
13.09.22	SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm (PR Newswire)
07.09.22	The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus (GlobeNewswire)
04.08.22	EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFE... (PR Newswire)
28.07.22	The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus (GlobeNewswire)
26.07.22	FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS (GlobeNewswire)
21.07.22	ABT Raises Earnings Forecast, BIIB Provides Rosy Revenue Outlook, ELV Q2 Revenue Up 15.6% (RTTNews)
20.07.22	Biogen Boosts FY22 Outlook As Q2 Results Top Estimates (RTTNews)
20.07.22	Current report (RSS)
19.07.22	Ausblick: Biogen zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
06.07.22	Post-Effective amendments for registration statement (RSS)
06.07.22	THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY (PR Newswire)
21.06.22	European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) (GlobeNewswire)
15.06.22	New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen) (GlobeNewswire)
08.06.22	Biogen zieht Schweizer Zulassungsgesuch von Alzheimer-Medikament zurück (AWP)
06.06.22	Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease (GlobeNewswire)
03.06.22	Biogen, Bio-Thera Presents Positive Phase 3 Data For Tocilizumab Biosimilar In Rheumatoid Arthritis (RTTNews)
03.06.22	Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022) (GlobeNewswire)
03.06.22	Ionis: Tofersen Slows Disease Progression In Phase 3 VALOR Study (RTTNews)
03.06.22	New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS (GlobeNewswire)
17.05.22	Registration of securities, business combinations (RSS)
10.05.22	EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY (PR Newswire)
05.05.22	Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis (GlobeNewswire)
03.05.22	Biogen-Aktie im Plus: Konzernchef muss gehen (AWP) Die US-Biotechnologiefirma Biogen zieht nach den Schwierigkeiten mit ihrem umstrittenen Alzheimer-Medikament personelle Konsequenzen und will ihren Chef austauschen.» mehr
03.05.22	Biogen Reaffirms FY22 Outlook; Q1 Adj. EPS Misses Estimates (RTTNews)
02.05.22	Ausblick: Biogen informiert über die jüngsten Quartalsergebnisse (finanzen.net)
29.04.22	Form DEF 14A 875045 (RSS)
18.04.22	Erste Schätzungen: Biogen verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
04.04.22	New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression (GlobeNewswire)
30.03.22	Biogen Submits Final Protocol For Envision Trial Of Aduhelm On Alzheimer's Disease (RTTNews)
30.03.22	Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA (GlobeNewswire)
28.03.22	Biogen : Phase 1 Study Of BIIB078 On Amyotrophic Lateral Sclerosis Fails To Meet Secondary Endpoints (RTTNews)
28.03.22	Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis (GlobeNewswire)
28.03.22	Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis (PR Newswire)
22.03.22	LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING (PR Newswire)
18.03.22	Viatris Says Defeats Biogen's Attempt To Revive Tecfidera Patent (RTTNews)
16.03.22	Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease (GlobeNewswire)
16.03.22	Biogen: ADUHELM Continues To Reduce Underlying Pathologies Of Alzheimer's Beyond Two Years (RTTNews)
16.03.22	Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years (GlobeNewswire)
15.03.22	Biogen, Eisai Amend Collaboration Agreement On Alzheimer's Disease Treatments (RTTNews)
15.03.22	Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments (GlobeNewswire)
14.03.22	Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference (GlobeNewswire)
11.03.22	Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022) (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

24.12.24		Börse New York: Dow Jones zeigt sich zum Handelsende fester
24.12.24		Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen
24.12.24		Dow Jones-Handel aktuell: Dow Jones steigt am Dienstagmittag
24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
24.12.24		NYSE-Handel: Dow Jones beginnt Dienstagshandel mit Gewinnen

24.12.24

Börse New York: Dow Jones zeigt sich zum Handelsende fester

24.12.24

Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen

24.12.24

Dow Jones-Handel aktuell: Dow Jones steigt am Dienstagmittag

24.12.24

Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu

24.12.24

Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50

24.12.24

Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone